Multiple binding of bepridil in human blood

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Biochemistry
• Analytical Chemistry

Background:

• Understanding drug binding to blood components is crucial for predicting distribution and efficacy.
• Bepridil is a calcium channel blocker with known interactions with biological molecules.

Purpose of the Study:

• To characterize the binding of bepridil to human serum proteins, blood cells, and platelets.
• To determine the binding parameters and identify major binding sites and components.

Main Methods:

• Utilized radiolabelled bepridil for equilibrium dialysis and direct ligand-binding studies.
• Quantified binding affinities (K) and capacities (n or N) to various blood components.
• Simulated bepridil distribution based on determined binding parameters.

Main Results:

• Bepridil exhibited significant binding to serum albumin and alpha 1-acid glycoprotein.
• Shared binding site on alpha 1-acid glycoprotein with other drugs (propranolol, quinidine, erythromycin).
• Non-specific binding to red blood cells (RBCs) and white blood cells (WBCs); saturable binding to platelets.

Conclusions:

• Serum albumin, alpha 1-acid glycoprotein, and RBCs are the primary determinants of bepridil distribution in blood.
• Binding characteristics provide insights into bepridil's pharmacokinetic profile and therapeutic range.